Cao Thai M, Coutre Steven E
Division of Hematology, 703 Welsh Road, Stanford University, School of Medicine, Stanford, CA 94305-5112, USA.
Curr Hematol Rep. 2003 Jan;2(1):65-72.
Chronic lymphocytic leukemia (CLL) is generally considered to be incurable. It is the most common of the adult leukemias, and many patients are asymptomatic when diagnosed. Most patients survive for several years, and some never require treatment for their disease, leading to the belief that it is an indolent disease. However, this view is changing with the introduction of more effective therapies. Purine nucleoside analogs have become standard in the therapy of most patients. Monoclonal antibodies including alemtuzumab (Campath-IH; Berlex Laboratories, Richmond, CA) and rituximab are playing an increasingly important role in the treatment of patients with advanced disease. Clinical trials will be crucial in defining how and when to treat patients with CLL and will help establish the role of newer prognostic markers and more sensitive methodologies to detect minimal residual disease.
慢性淋巴细胞白血病（CLL）通常被认为是无法治愈的。它是成人白血病中最常见的类型，许多患者在确诊时没有症状。大多数患者能存活数年，有些患者甚至从未因该病接受治疗，这导致人们认为它是一种惰性疾病。然而，随着更有效疗法的引入，这种观点正在发生变化。嘌呤核苷类似物已成为大多数患者治疗的标准用药。包括阿仑单抗（Campath-IH；Berlex实验室，加利福尼亚州里士满）和利妥昔单抗在内的单克隆抗体在晚期疾病患者的治疗中发挥着越来越重要的作用。临床试验对于确定如何以及何时治疗CLL患者至关重要，并且将有助于确立新的预后标志物以及检测微小残留病的更敏感方法的作用。
